The board lifted share repurchase authorization by USD 1 billion, leaving USD 1.4 billion remaining; the quarterly dividend was set at USD 0.72 per share.
Full-year 2026 guidance was raised to revenue growth of 5.4% to 6.3% and adjusted EPS of USD 18.10 to USD 18.55.
Labcorp reports higher Q2 2026 revenue and EPS
Labcorp Q2 2026 revenue rose 5.8% to USD 3.73 billion; diluted EPS climbed 28.5% to USD 3.64.
Operating income increased to USD 451.6 million, lifting operating margin 0.9 percentage point to 12.1%.
Diagnostics Laboratories revenue grew 5.5% to USD 2.9 billion; Biopharma Laboratory Services revenue increased 6.5% to USD 836.2 million.
LH•
